Timo K. Van Den Berg

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.

Journal: Journal for immunotherapy of cancer
Published: March 26, 2023

Neutrophils as immune effector cells in antibody therapy in cancer.

Neutrophils as immune effector cells in antibody therapy in cancer.

Journal: Immunological reviews
Published: November 04, 2022

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.

Journal: Cancers
Published: June 21, 2022

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.

Journal: Journal for immunotherapy of cancer
Published: May 23, 2022

Neutrophil phenotypes and functions in cancer: A consensus statement.

Neutrophil phenotypes and functions in cancer: A consensus statement.

Journal: The Journal of experimental medicine
Published: December 23, 2021

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells.

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells.

Journal: Cancers
Published: July 05, 2021

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.

Journal: Blood advances
Published: May 25, 2021

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

Journal: Journal for immunotherapy of cancer
Published: March 26, 2021

m6A methylation potentiates cytosolic dsDNA recognition in a sequence-specific manner.

m6A methylation potentiates cytosolic dsDNA recognition in a sequence-specific manner.

Journal: Open biology
Published: March 15, 2021

C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro.

C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro.

Journal: Frontiers in immunology
Published: August 14, 2020

Myeloid Ezh2 Deficiency Limits Atherosclerosis Development.

Myeloid Ezh2 Deficiency Limits Atherosclerosis Development.

Journal: Frontiers in immunology
Published: August 13, 2020

Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47-SIRPα Checkpoint Disruption.

Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47-SIRPα Checkpoint Disruption.

Journal: Cancer immunology research
Published: June 10, 2020
Showing 1-12 of 104

Last Updated: 09/26/2026